Corporate Disclosure2026-05-12
CJ Bioscience Cancels Trial
CJK
CJ 바이오사이언스
311690
Signal Score
50C — Neutral
Score50 / 100
Historical Avg Return (5d)
+0.03%
Data Coverage
100%n=9150
Risk-adjusted indicator based on 9150 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Clinical Trial Phase: Phase 1/2
- • Number of Patients: 46 (Phase 1), 120 (Phase 2)
4 more figures — unlock with API access
AI Analysis Summary
Developer & Pro plans
Risk Factors
Developer & Pro plans
Access Full Korean Market Signal Analytics
✔ AI-parsed DART filing classification & scoring
✔ Real-time event impact indicators
✔ Historical pattern data via REST API
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.
AI-processed analysis. Based on: 투자판단관련주요경영사항(임상시험계획자진취하등) . Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.